Xembify Market Report 2026

Xembify Market Overview

• The Xembify market growth in the historic period has been driven by increasing diagnosis rates of primary immunodeficiency diseases, wider availability of plasma-derived therapies • Market expansion is supported by increasing prevalence of chronic immune disorders, rising demand for self-administered therapies • Growth Driver: Rising Prevalence Of Primary Immunodeficiency Diseases Boosts The Market • Market Trend: Innovations In Subcutaneous Immunoglobulin For Primary Immunodeficiencies • North America was the largest region in 2025.

What Is Covered Under Xembify Market?

Xembify is a brand name for a medication called immune globulin subcutaneous (human), used to treat primary immunodeficiency diseases (PIDD) and chronic inflammatory demyelinating polyneuropathy (CIDP). It is a type of immunoglobulin therapy that helps boost the immune system by providing the body with antibodies (immunoglobulins) that it may not produce adequately. The main types of indications for xembify are primary immunodeficiency, secondary immunodeficiency, chronic inflammatory demyelinating polyneuropathy (CIDP), Guillain-Barré syndrome, immune thrombocytopenia (ITP), and multifocal motor neuropathy (MMM). Primary immunodeficiency is a group of genetic disorders characterized by defects in the immune system, leading to increased susceptibility to infections and immune-related complications. It is distributed through various distribution channels, such as direct sales, pharmacies, and online retailers. Also, it is used by several end users, including hospitals, clinics, and home care settings.

What Is The Xembify Market Growth Forecast?

The growth in the forecast period can be attributed to increasing prevalence of chronic immune disorders, rising demand for self-administered therapies, expansion of homecare infusion services, growing investments in plasma collection infrastructure, ongoing advancements in immunoglobulin formulation science. Major trends in the forecast period include increasing adoption of subcutaneous immunoglobulin therapies, rising preference for home-based immunoglobulin administration, growing focus on patient-centric treatment protocols, expansion of long-term immunodeficiency management solutions, improved stability and formulation advancements.

What Are The Drivers Of The Xembify Market?

The rising prevalence of primary immunodeficiency diseases (PI) is expected to drive the growth of the xembify market moving forward. Primary immunodeficiency diseases refer to disorders where the immune system is deficient or absent, impairing the body's ability to fight infections and leading to increased susceptibility to illnesses. The prevalence of primary immunodeficiency diseases (PI) is due to advancements in diagnostic techniques, greater awareness and recognition of these conditions, improved genetic testing, and the better identification of previously undiagnosed cases. Xembify is crucial in managing PI by delivering immunoglobulin therapy to enhance the immune system and improve patient outcomes. For instance, in August 2023, according to a report published by Thermo Fisher, a US-based life science and clinical research company, approximately 6 million people globally are estimated to have a primary immunodeficiency (PID), with around 5,000 individuals in the UK affected by the disorder. Therefore, the rising prevalence of primary immunodeficiency diseases (PI) is expected to drive the growth of the xembify industry. The rising healthcare spending is expected to drive the growth of the xembify market going forward. Healthcare spending refers to the total resources governments, private entities, and individuals allocate towards healthcare services, including medical research, infrastructure, treatment options, preventive measures, and innovative therapies. The increase in healthcare spending is due to factors such as the growing prevalence of chronic and rare diseases, advancements in medical technology, rising healthcare awareness, aging populations, and an increasing focus on improving healthcare infrastructure. Increased healthcare spending supports awareness campaigns and screening programs for Primary Immunodeficiency Diseases. Early diagnosis leads to earlier intervention with treatments like Xembify, boosting adoption. For instance, in December 2024, according to the Centers for Medicare & Medicaid Services, a US-based agency responsible for administering the Medicare and Medicaid programs, in 2023, U.S. health care expenditures increased by 7.5%, climbing to $4.9 trillion, or roughly $14,570 for each individual. Therefore, rising healthcare spending boosts the growth of the xembify industry.

Key Players In The Global Xembify Market

Major companies operating in the xembify market are Grifols S.A.

Global Xembify Market Trends and Insights

The key trend in the xembify market is expanding indications, such as the 20% subcutaneous immunoglobulin (SCIg) product, to provide more flexible dosing options for patients with primary immunodeficiency and other immune-related conditions. The 20% subcutaneous immunoglobulin (SCIg) product is a medication used to treat primary immunodeficiency and other immune-related conditions, providing a concentrated form of immunoglobulin G (IgG) administered through subcutaneous injection to boost the immune system. For instance, in July 2024, Grifols, S.A., a Spain-based pharmaceutical and chemical manufacturer, received approval from the U.S. Food and Drug Administration (FDA) for an expanded label of its 20% subcutaneous immunoglobulin (SCIg) product, XEMBIFY, to include treatment-naïve patients with primary humoral immunodeficiencies (PI). This approval marked XEMBIFY as the first 20% SCIg therapy that can be administered without prior intravenous treatment, offering greater flexibility and convenience to patients. This milestone reinforces Grifols’ commitment to improving patient outcomes by providing innovative and patient-friendly immunoglobulin therapies.

What Defines the Xembify Market?

The xembify market consists of sales of pre-filled syringes, vials, infusion pumps, administration sets, and other required tools. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Xembify Market Report 2026?

The xembify market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the xembify industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.